Loading data for CVM — first visit, this takes a few seconds.
CEL-SCI Corporation (CVM)
NYSE American: CVM
· 即時價格 · USD
1.61
-0.04 (-2.42%)
收盤價： Sep 03, 2026, 8:00 PM
1.61
+0.29%
盤後: 7:55 PM
股價、關鍵數字和最新消息，都在這一頁。
CEL-SCI Corporation（CVM）股價、分析與資料
無可用資料
| 買價 | 1.61 |
| 市值 | 28.3M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -22.7M |
| 0.56 | |
| -1.69 | |
| n/a | |
| -0.25 | |
| P/B (ttm) | 2.58 |
| P/S (ttm) | 0.00 |
| 財報日期 | Feb 12, 2026 |
| 賣價 | 1.63 |
| 成交量 | 116,052 |
| 20 日平均成交量 | 315,212 |
| 開盤價 | 1.65 |
| 前收盤價 | 1.65 |
| 當日區間 | 1.60 - 1.68 |
| 52 週範圍 | 0.89 - 12.53 |
| 分析師 | n/a |
| 目標價 | 12.5 (676.4%) |
| 股利 | n/a |
| 除息日 | Aug 28, 1996 |
關於 CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulat...
完整的公司簡介財報驚奇
CEL-SCI 已於 Jan 13, 2025 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -2.7 超出預期 0.60, 年增 43.75% 成長.
